InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
March 05 2021 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a
research and clinical-stage biomaterials and biotechnology company
with a focus on the treatment of spinal cord injuries, today
announced that Richard Toselli, M.D., President and Chief Executive
Officer, will present at the upcoming 2021 H.C. Wainwright Global
Life Sciences Conference. The conference is scheduled to be held
March 9-10, 2021 in a virtual format. Dr. Toselli’s presentation
will provide an overview of the company and highlight key business
updates for the company.
A webcast of the presentation will be available on the Investor
Relations - Events section of the InVivo website at
https://investors.invivotherapeutics.com/events beginning March 9,
2021 at 7:00 am ET. In addition to the company’s presentation, Dr.
Toselli and company management will be available to participate in
one-on-one meetings with investors who are registered to attend the
conference.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210305005052/en/
Investor Contact:
Bret Shapiro, Managing Partner CORE IR brets@coreir.com (516)
222-2560
Media Contact
Gina Nugent Ten Bridge Communications
gina@tenbridgecommunications.com 617-460-3579
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024